ArticleFrontiers in public health2022

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis.

Mingyang Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.